CME/CE Accreditation Information Return to Previous

Jointly provided by the Postgraduate Institute for Medicine and DKBmed, LLC.

Target Audience

This activity has been designed to meet the educational needs of clinicians involved in the care of patients with osteoarthritis or who require pain management.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Identify manifestations of the burden of OA pain, including comorbidities and racial and gender disparities in treatment, and evaluate their impact on patient quality of life.
  • Describe current nonpharmacologic and pharmacologic OA treatments and identify how they are failing to meet patients’ needs.
  • Evaluate the nerve growth factor (NGF) pathway and how medications blocking NGF may benefit patients with OA.
  • Identify benefits and risks of in-development NGF-sequestering agents for treating OA.

Joint Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed, LLC. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.25 contact hours.

Media: Internet


This activity is supported by an independent educational grant from Pfizer, Inc.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty / Presenter Reported Financial Relationship

Yvonne D’Arcy, MS, ARNP-C, CNS, FAANP

  • Royalty - Springer Publishing
  • Consulting Fees (e.g., advisory boards) - Salix, Lilly advisory boards
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus) - Salix for OIC
  • Other editorial support and online presentation - Pfizer, Lilly (unpaid editorial support), REMS on the Frontline, CME Zone-online presentation, Buprenorphine article for Pain Medicine News, CMEZone

Bill McCarberg, MD

  • Consulting Fees (e.g., advisory boards) - Lilly, Scilex, Averitas
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus) - Adapt, Scilex
  • Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds) - Johnson and Johnson

Planners and Managers

The PIM planners and managers have nothing to disclose. The DKBmed planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Request for Credit

There are no fees for participating and receiving CME/CE credit for this activity.

If you wish to receive acknowledgment for completing this activity, please complete the evaluation.

Launch: April 30, 2021
Expiration: June 01, 2022


Contact Information

If you have questions regarding CE, please contact PIM via email at

For technical issues, please contact